INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary Nantkwest and Frankfurt University Hospital Announce First in Human Dosing of off-the-Shelf HER2.taNK (Car–natural Killer) Cell Therapy in Glioblastoma
CULVER CITY, Calif. --(BUSINESS WIRE)--Feb. 13, 2018-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, today announced that
View HTML
Toggle Summary Dr. Patrick Soon-Shiong Presents at the 36th Annual J.P. Morgan Healthcare Conference
Download Presentation (PDF) To watch the Webcast To Listen to the Webcast
View HTML
Toggle Summary Nantworks To Present Healthcare And Biotechnology Platforms At 36th Annual J.P. Morgan Healthcare Conference On January 9, 2018 In San Francisco, CA
Announces a Record 25 Letters of Authorization to Proceed with Clinical Trials Covering 12 Novel Biological Molecules in 20 Tumor Types January 5, 2018 — Culver City, California — NantWorks , the parent organization of NantHealth (NASDAQ: NH) and NantKwest (NASDAQ: NK) announced today that Dr.
View HTML
Toggle Summary NantKwest to Host 3rd Annual Investor/Analyst Day Highlighting a Record Number of 15 INDs Authorized in 2017 Covering 12 Tumor Types with First In-Human Clinical Data of Safety and Early Signs of Clinical Activity of the NANT Cancer Vaccine
CULVER CITY, Calif. --(BUSINESS WIRE)--Jan. 5, 2018-- NantKwest (NASDAQ: NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the human immune system using natural killer (NK) cells to treat cancer, announced today that the company will
View HTML
Toggle Summary NantKwest to Present Data at the 59th Annual Meeting of the American Society of Hematology
Oral Presentation to Highlight Preclinical Data on a Chimeric Antigen Receptor (CAR) Engineered Natural Killer Cell Therapy (CD19.taNK) in CD Resistant B-Cell Non-Hodgkin Lymphoma CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 4, 2017-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation,
View HTML
Toggle Summary NantKwest Announces Successful First in Human Administration of CD16 High Affinity Natural Killer (haNK) Cells
Successful Administration Of Off The Shelf Hank Cells In Patients With Solid Tumors Paves The Way To Nation's First Combination Innate And Adaptive NANT Cancer Vaccine Trials In Multiple Tumor Types CULVER CITY, Calif. --(BUSINESS WIRE)--Oct. 2, 2017-- NantKwest Inc.
View HTML
Toggle Summary NantKwest Builds Financial and Commercial Expertise with the Appointment of Fred Driscoll to Its Board of Directors
CULVER CITY, Calif. --(BUSINESS WIRE)--Sep. 22, 2017-- NantKwest, Inc. (Nasdaq:NK) today announced that Fred Driscoll , currently an Advisor and former Chief Financial Officer of Flexion Therapeutics, Inc. , has been appointed to the Board to fill the position being vacated by Mr.
View HTML
Toggle Summary NantKwest to Present at Upcoming Investment Conferences
CULVER CITY, CALIFORNIA-(BUSINESS WIRE), September 5, 2017 NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting at three investment conference in September.
View HTML
Toggle Summary NantKwest to Present at the 37th Annual Canaccord Genuity Growth Conference
CULVER CITY, Calif. --(BUSINESS WIRE)--Aug. 7, 2017-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell-based therapeutics company, today announced that the company will be presenting at the 37 th Annual Canaccord Genuity Growth Conference taking place August 9-10, 2017 in
View HTML
Toggle Summary NantKwest Announces Durable Complete Responses in Phase I Trial of aNK Cell Therapy in Patients with Relapsed Hematological Malignancies
42% Of Patents Exhibited A Response, With Two Complete Responses In A Phase 1 Study Of 12 Patients With A Patient In Complete Remission 10 Years After Failing Transplant Therapy For Hodgkin’s Lymphoma, And A Second Patient In Complete Remission 2 Years After Failing Transplant Therapy In Multiply
View HTML